BD Achieves Key Surgical Milestone with First Phasix™ Hernia Prevention Case in Greece and Strong Enrollment in U.S. PREVENT Trial

BD (Becton, Dickinson and Company), a major global medical technology firm, announced a significant advancement in hernia prevention on January 5, 2026. The company completed the first Phasix™ Mesh laparotomy reinforcement case in Greece under the expanded European indication for prophylactic use, marking the first broad preventive application of this hernia mesh in high‑risk open surgeries across the EU. The procedure was performed at George Papanikolaou General Hospital in Thessaloniki on a 63‑year‑old male patient with multiple risk factors, where the bioabsorbable mesh was placed prophylactically to help reduce future hernia risk. At the same time, BD’s PREVENT multicenter randomized controlled trial — conducted at sites across Europe and the United States — has now treated more than 85% of its target enrollment and is on track to complete patient recruitment in 2026. This study is designed to generate strong clinical evidence for the effectiveness of prophylactic bioabsorbable mesh in reducing incisional hernia rates and to support a future PMA submission for hernia prevention in the United States. BD highlighted that incisional hernias occur in up to 30% of abdominal surgery patients and represent significant cost burdens for health systems. With Phasix™ Mesh now CE‑marked for broad prophylactic use and available across Europe, the company believes this milestone supports its strategy to improve surgical outcomes and reduce long‑term complications. #HerniaPrevention #PhasixMesh #ClinicalTrials #MedicalInnovation #SlimScan #GrowthStocks #CANSLIM